Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT01959633 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation(VEMUPLINT) | completed | Phase 1 / Phase 2 | 11 | Fondazione Melanoma OnlusOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02482532 | Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma(MARVSmALo) | completed | Phase 1 | 7 | Gary DoolittleOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT03278665 | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy(SENSITIZE) | completed | Phase 1 / Phase 2 | 40 | 4SC AGINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02225366 | Intratumoral Injections of LL37 for Melanoma | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 27 | University of LouisvilleOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02983006 | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | completed | Phase 1 / Phase 2 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02112032 | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | completed | Phase 1 | 43 | Hassane M. Zarour, MDOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT00118274 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 170 | Craig L Slingluff, JrOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | completed | Phase 1 | 31 | Kartos Therapeutics, Inc.INDUSTRY | 2 | Mar 26, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00398450 | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | University of California, San DiegoOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02339324 | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | completed | Phase 1 | 31 | Yana NajjarOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | completed | Phase 1 | 149 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 10, 2020 | clinicaltrials |
| NCT00005617 | Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00090896 | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | completed | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01005472 | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00498979 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | completed | Phase 1 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | completed | Phase 1 | 84 | Immunocore LtdINDUSTRY | 2 | Jul 8, 2020 | clinicaltrials |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma(X4P-001-MELA) | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | completed | Phase 1 | 39 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01897116 | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | completed | Phase 1 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 31, 2022source: clinicaltrials